141 related articles for article (PubMed ID: 35367201)
21. ASCL1 and RET expression defines a clinically relevant subgroup of lung adenocarcinoma characterized by neuroendocrine differentiation.
Kosari F; Ida CM; Aubry MC; Yang L; Kovtun IV; Klein JL; Li Y; Erdogan S; Tomaszek SC; Murphy SJ; Bolette LC; Kolbert CP; Yang P; Wigle DA; Vasmatzis G
Oncogene; 2014 Jul; 33(29):3776-83. PubMed ID: 24037524
[TBL] [Abstract][Full Text] [Related]
22. Somatostatin receptor expression related to TP53 and RB1 alterations in pancreatic and extrapancreatic neuroendocrine neoplasms with a Ki67-index above 20.
Konukiewitz B; Schlitter AM; Jesinghaus M; Pfister D; Steiger K; Segler A; Agaimy A; Sipos B; Zamboni G; Weichert W; Esposito I; Pfarr N; Klöppel G
Mod Pathol; 2017 Apr; 30(4):587-598. PubMed ID: 28059098
[TBL] [Abstract][Full Text] [Related]
23. Growth suppression by MYC inhibition in small cell lung cancer cells with TP53 and RB1 inactivation.
Fiorentino FP; Tokgün E; Solé-Sánchez S; Giampaolo S; Tokgün O; Jauset T; Kohno T; Perucho M; Soucek L; Yokota J
Oncotarget; 2016 May; 7(21):31014-28. PubMed ID: 27105536
[TBL] [Abstract][Full Text] [Related]
24. DLL3 expression in large cell neuroendocrine carcinoma (LCNEC) and association with molecular subtypes and neuroendocrine profile.
Hermans BCM; Derks JL; Thunnissen E; van Suylen RJ; den Bakker MA; Groen HJM; Smit EF; Damhuis RA; van den Broek EC; ; Ruland A; Speel EJM; Dingemans AMC
Lung Cancer; 2019 Dec; 138():102-108. PubMed ID: 31678831
[TBL] [Abstract][Full Text] [Related]
25. A first case of ductal adenocarcinoma of the prostate having characteristics of neuroendocrine phenotype with PTEN, RB1 and TP53 alterations.
Kobayashi H; Kosaka T; Nakamura K; Shojo K; Hongo H; Mikami S; Nishihara H; Oya M
BMC Med Genomics; 2021 Oct; 14(1):245. PubMed ID: 34627261
[TBL] [Abstract][Full Text] [Related]
26. NET G3 vs NEC: p53 and Rb1 Immunolabeling in High-grade Gastrointestinal Neuroendocrine Neoplasms - Is It Enough for the Differential Diagnosis?
Dinu A; Aschie M; Cozaru GC; Mitroi AF; Grasa CN; Iordache IE; Deacu M; Orasanu CI; Nicolau AA; Baltatescu GI
J Gastrointestin Liver Dis; 2023 Jun; 32(2):162-169. PubMed ID: 37345605
[TBL] [Abstract][Full Text] [Related]
27. EGFR mediates activation of RET in lung adenocarcinoma with neuroendocrine differentiation characterized by ASCL1 expression.
Bhinge K; Yang L; Terra S; Nasir A; Muppa P; Aubry MC; Yi J; Janaki N; Kovtun IV; Murphy SJ; Halling G; Rahi H; Mansfield A; de Andrade M; Yang P; Vasmatzis G; Peikert T; Kosari F
Oncotarget; 2017 Apr; 8(16):27155-27165. PubMed ID: 28460442
[TBL] [Abstract][Full Text] [Related]
28. Molecular pathology of small cell lung cancer: Overview from studies on neuroendocrine differentiation regulated by ASCL1 and Notch signaling.
Ito T
Pathol Int; 2024 May; 74(5):239-251. PubMed ID: 38607250
[TBL] [Abstract][Full Text] [Related]
29. ASCL1 represses a SOX9
Olsen RR; Ireland AS; Kastner DW; Groves SM; Spainhower KB; Pozo K; Kelenis DP; Whitney CP; Guthrie MR; Wait SJ; Soltero D; Witt BL; Quaranta V; Johnson JE; Oliver TG
Genes Dev; 2021 Jun; 35(11-12):847-869. PubMed ID: 34016693
[TBL] [Abstract][Full Text] [Related]
30. ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs.
Borromeo MD; Savage TK; Kollipara RK; He M; Augustyn A; Osborne JK; Girard L; Minna JD; Gazdar AF; Cobb MH; Johnson JE
Cell Rep; 2016 Aug; 16(5):1259-1272. PubMed ID: 27452466
[TBL] [Abstract][Full Text] [Related]
31. Clonality Analysis for the Relationship between the Pulmonary Combined Neuroendocrine Carcinoma and "the So-Called Reported Histologic Transformation".
Wang H; Zhu Y; Sun W; Yang X; Liu X; Chi K; Huang X; Zhou L; Cai W; Lin D
Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067352
[TBL] [Abstract][Full Text] [Related]
32. Molecular Classification of Extrapulmonary Neuroendocrine Carcinomas With Emphasis on POU2F3-positive Tuft Cell Carcinoma.
Koh J; Kim H; Moon KC; Lee C; Lee K; Ryu HS; Jung KC; Jeon YK
Am J Surg Pathol; 2023 Feb; 47(2):183-193. PubMed ID: 36253891
[TBL] [Abstract][Full Text] [Related]
33. Genetic and Immunohistochemical Studies Investigating the Histogenesis of Neuroendocrine and Carcinomatous Components of Combined Neuroendocrine Carcinoma.
Iijima M; Yokobori T; Mogi A; Shimizu K; Yajima T; Kosaka T; Ohtaki Y; Obayashi K; Nakazawa S; Gombodorj N; Tsukagoshi M; Shirabe K; Kuwano H
Ann Surg Oncol; 2019 Jun; 26(6):1744-1750. PubMed ID: 30924018
[TBL] [Abstract][Full Text] [Related]
34. In-depth molecular analysis of combined and co-primary pulmonary large cell neuroendocrine carcinoma and adenocarcinoma.
Hermans BCM; Derks JL; Hillen LM; van der Baan I; van den Broek EC; von der Thüsen JH; van Suylen RJ; Atmodimedjo PN; den Toom TD; Coumans-Stallinga C; Timens W; Dinjens WNM; Dubbink HJ; Speel EM; Dingemans AC;
Int J Cancer; 2022 Mar; 150(5):802-815. PubMed ID: 34674268
[TBL] [Abstract][Full Text] [Related]
35. Case report: EGFR-mutant lung adenocarcinoma with the TP53 and RB1 mutations showed resistance to TKI therapy.
Lu Y; Li Z; Zhu H; Zhao J; Xu M; Gu W
Ann Palliat Med; 2021 Dec; 10(12):12886-12893. PubMed ID: 35016432
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathological and genomic features in patients with head and neck neuroendocrine carcinoma.
Ohmoto A; Sato Y; Asaka R; Fukuda N; Wang X; Urasaki T; Hayashi N; Sato Y; Nakano K; Yunokawa M; Ono M; Tomomatsu J; Toshiyasu T; Mitani H; Takeuchi K; Mori S; Takahashi S
Mod Pathol; 2021 Nov; 34(11):1979-1989. PubMed ID: 34247193
[TBL] [Abstract][Full Text] [Related]
37. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
Manzano RG; Catalan-Latorre A; Brugarolas A
BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
[TBL] [Abstract][Full Text] [Related]
38. Small cell lung cancer, an epithelial to mesenchymal transition (EMT)-like cancer: significance of inactive Notch signaling and expression of achaete-scute complex homologue 1.
Ito T; Kudoh S; Ichimura T; Fujino K; Hassan WA; Udaka N
Hum Cell; 2017 Jan; 30(1):1-10. PubMed ID: 27785690
[TBL] [Abstract][Full Text] [Related]
39. Implication of cytoplasmic p53 expression in pulmonary neuroendocrine carcinoma using next-generation sequencing analysis.
Jimbo N; Ohbayashi C; Fujii T; Takeda M; Mitsui S; Tsukamoto R; Tanaka Y; Itoh T; Maniwa Y
Histopathology; 2024 Jan; 84(2):336-342. PubMed ID: 37814580
[TBL] [Abstract][Full Text] [Related]
40. Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets.
Rekhtman N; Pietanza MC; Hellmann MD; Naidoo J; Arora A; Won H; Halpenny DF; Wang H; Tian SK; Litvak AM; Paik PK; Drilon AE; Socci N; Poirier JT; Shen R; Berger MF; Moreira AL; Travis WD; Rudin CM; Ladanyi M
Clin Cancer Res; 2016 Jul; 22(14):3618-29. PubMed ID: 26960398
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
